Henry Schein (HSIC) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
15 Sep, 2026Executive summary
Achieved strong Q2 2026 results with total sales up 6.7% year-over-year to $3.5 billion and internal local currency sales growth of 4.6%; non-GAAP diluted EPS rose 15.5% to $1.27, and GAAP diluted EPS increased to $0.82.
Value creation initiatives and operational rigor drove earnings growth, with early benefits supporting double-digit earnings growth expectations for 2027.
Raised full-year 2026 guidance based on strong first-half performance and sustained momentum across dental, medical, and technology segments.
Focused on accelerating growth, simplifying operations, and deepening customer relationships to create sustainable shareholder value.
Technology platforms, especially AI-enabled and cloud-based solutions, are key growth drivers.
Financial highlights
Q2 2026 global sales reached $3.5 billion, up 6.7% year-over-year; internal local currency sales growth was 4.6%.
Non-GAAP operating income grew 10.5% to $250 million; non-GAAP EPS rose 15.5% to $1.27; adjusted EBITDA increased 12.7% to $288 million.
GAAP net income for Q2 2026 was $94 million ($0.82/diluted share); non-GAAP net income was $145 million ($1.27/diluted share).
Gross margin improved to 31.8% (non-GAAP); Q2 2026 operating margin was 4.94% (GAAP) and 7.21% (non-GAAP).
Operating cash flow for Q2 2026 was $242 million; share repurchases totaled $200 million in Q2, with $455 million remaining authorized.
Outlook and guidance
FY2026 total sales growth expected at 4.5%–5.5%; non-GAAP diluted EPS guidance raised to $5.29–$5.39; adjusted EBITDA growth projected at mid to high single digits.
Guidance excludes restructuring, amortization, remeasurement gains, and tariff refunds; assumes stable FX rates.
Earnings growth in Q4 expected to exceed Q3, driven by sales momentum and value creation benefits.
The restructuring plan is expected to continue through 2027, with further charges anticipated.
Latest events from Henry Schein
- Technology, mix shift and productivity underpin growth and value-creation targets.HSIC
Jefferies Global Healthcare Conference - FY2025 sales grew 4%, with a 2027 target to source over half of non-GAAP operating income from high-growth businesses.HSIC
Corporate presentation - Q3 sales rose 4%, adjusted EPS grew 19.1%, and FY2026 EPS guidance increased.HSIC
Q3 2026 - Growth acceleration, operational rigor, and disciplined capital allocation drive strong performance.HSIC
2026 Global Healthcare Conference - Global leader in dental and medical products with $13.2B sales and strong growth momentum.HSIC
Corporate presentation - Lowery’s appointment, share gains and a $200M+ plan underpin growth and BOLD+1 execution.HSIC
44th Annual J.P. Morgan Healthcare Conference - Record Q3 2025 results, raised guidance, and $200M+ value creation initiatives announced.HSIC
Q3 2025 - Q2 2024 sales up 1.1% to $3.14B; net income and EPS declined, and guidance was reduced.HSIC
Q2 2024 - Q4 2024 non-GAAP EPS rose 80% on 5.8% sales growth; 2025 outlook targets steady gains.HSIC
Q4 2024